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ABSTRACT
Osteoarthritis affects the whole joint structure with
progressive changes in cartilage, menisci, ligaments and
subchondral bone, and synovial inﬂammation. Biomarkers
are being developed to quantify joint remodelling and
disease progression. This article was prepared following
a working meeting of the European Society for Clinical
and Economic Aspects of Osteoporosis and Osteoarthritis
convened to discuss the value of biochemical markers of
matrix metabolism in drug development in osteoarthritis.
The best candidates are generally molecules or molecular
fragments present in cartilage, bone or synovium and
may be speciﬁc to one type of joint tissue or common to
them all. Many currently investigated biomarkers are
associated with collagen metabolism in cartilage or
bone, or aggrecan metabolism in cartilage. Other
biomarkers are related to non-collagenous proteins,
inﬂammation and/or ﬁbrosis. Biomarkers in osteoarthritis
can be categorised using the burden of disease,
investigative, prognostic, efﬁcacy of intervention,
diagnostic and safety classiﬁcation. There are a number
of promising candidates, notably urinary C-terminal
telopeptide of collagen type II and serum cartilage
oligomeric protein, although none is sufﬁciently
discriminating to differentiate between individual patients
and controls (diagnostic) or between patients with
different disease severities (burden of disease), predict
prognosis in individuals with or without osteoarthritis
(prognostic) or perform so consistently that it could
function as a surrogate outcome in clinical trials (efﬁcacy
of intervention). Future avenues for research include
exploration of underlying mechanisms of disease and
development of new biomarkers; technological
development; the ‘omics’ (genomics, metabolomics,
proteomics and lipidomics); design of aggregate scores
combining a panel of biomarkers and/or imaging
markers into single diagnostic algorithms; and
investigation into the relationship between biomarkers
and prognosis.
INTRODUCTION
Osteoarthritis manifests as alteration of the whole
joint structure, including progressive degradation of
cartilage, menisci and ligaments, synovial inﬂamma-
tion and changes to the subchondral bone.1 The
diagnosis of osteoarthritis is currently based on
radiographic criteria (eg, joint space width) and
clinical symptoms (eg, pain and loss of function).1
The evaluation of new disease-modifying osteoarth-
ritis drugs (DMOADs) is performed on the same
basis, since the regulatory bodies currently require
evidence for an impact on radiographic joint space
narrowing ( JSN) and an impact on symptoms.2 3
However, the limitations of radiography (eg, tech-
nical issues, precision and sensitivity)4 have led to
research into alternative parameters for monitoring
osteoarthritis that could serve as biomarkers in
drug development. The National Institutes of
Health (NIH) deﬁnes a biomarker as ‘a characteris-
tic that is objectively measured and evaluated as an
indicator of normal biologic processes, pathogenic
processes, or pharmacologic responses to a thera-
peutic intervention.’5
Imaging markers, from magnetic resonance and
ultrasound, may be useful biomarkers in the evalu-
ation of osteoarthritis and in drug development in
the ﬁeld.4 6 7 A promising outcome is the use of
quantitative MRI to assess changes in cartilage
volume or thickness. However, widespread use of
MRI is limited by cost, availability and the absence
of a validated international score. These imaging
markers are beyond the scope of this review and
the use of MRI is covered in a separate European
Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO).8
Another attractive alternative is the measurement
of biochemical markers in blood, urine or synovial
ﬂuid samples, which could reﬂect dynamic and
quantitative changes in joint remodelling and there-
fore disease progression. In the setting of osteoarth-
ritis, a biochemical marker could be either an
effector molecule (ie, an operator of joint damage),
the result of joint damage, or both, as in the case
of cartilage extracellular matrix fragments, such an
hyaluronan, that serve as both biomarkers and
stimuli of the innate immune chronic wound
healing response in the osteoarthritic joint.9 Such
biomarkers may be useful in early phase evaluation
of the efﬁcacy and safety of DMOADs and may
also ﬁnd applications in the diagnosis of disease,
the assessment of severity and the risk of progres-
sion and the monitoring of health status in the
general population.5 Insofar as current diagnostic
methods in osteoarthritis combine radiographic and
clinical signs, the disease is deﬁnitively diagnosed
only when destruction of joint tissue is irreversible.
Hence, an important characteristic of a new bio-
chemical marker should also be that it can detect
early osteoarthritis. Candidate biomarkers in osteo-
arthritis should also have proven validity, reprodu-
cibility and predictive value, and there should be
ample information on how they relate to processes
in the joint and clinical endpoints (such as
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structural damage, pain or dysfunction and/or joint replace-
ment). Despite much active research into biomarkers in osteo-
arthritis,10–16 no single biomarker stands out as the gold
standard or is sufﬁciently well validated and recognised for sys-
tematic use in drug development. In the light of this situation,
the ESCEO convened a working meeting in October 2012 with
a group of experts in the ﬁeld to discuss the value of biomarkers
in drug development in osteoarthritis, with a focus on the
potential avenues for future research. This article is a summary
of these discussions, and the manuscript was revised by the par-
ticipants of the meeting, as well as additional invited authors,
who provided further substantial input.
METHODS
Relevant articles, reviews and abstracts were identiﬁed through a
PubMed/MEDLINE and EMBASE search of English language
articles published between 1994 and September 2012. The
initial search strategy included the terms: osteoarthritis, bio-
marker, biological marker, CTX-I, CTX-II, CPII, C2/C, NTX-I,
PINP, OC, COMP, CS846, PIIANP, HA, PIIINP, leptin, adipo-
nectin, visfatin, leptin-receptor, adiponectin receptor, interleu-
kin, C-terminal and N-terminal telopeptides of collagen I,
aminoterminal propeptide of type I procollagen, osteocalcin,
cartilage oligomeric matrix protein, chondroitin sulphate 846,
soluble receptor for advanced glycation endproducts (sRAGE),
RAGE, type IIA collagen N-propeptide, matrix metalloprotei-
nase, cartilage glycoprotein 39 (YKL-40), uric acid, prostaglan-
din, bone turnover, drug effect, cartilage articular/drug effect,
outcome assessment and treatment outcome. The initial search
yielded 149 items. Separate subsearches were also performed
using a cross-search of the above terms combined, as well as the
reference lists of the selected articles and the presentations
made during the ESCEO meeting. Overall, 66 relevant items
were selected by the authors according to their quality and per-
tinence for discussion by the ESCEO working group.
CANDIDATE BIOMARKERS IN OSTEOARTHRITIS
The best candidates for biomarkers in osteoarthritis are most
likely to be structural molecules or fragments linked to cartilage,
bone or synovium and may be speciﬁc to one type of joint
tissue or common to them all. They may represent tissue deg-
radation or tissue synthesis and may be measured in synovial
ﬂuid, blood or urine. Box 1 and ﬁgure 1 outline a selection of
the various biomarkers that are currently being tested in osteo-
arthritis.10–20 Figure 1 highlights the different compartments of
the joint and potential biomarkers, all of which require careful
investigation. The cartilage, bone and synovial tissues all have
different potential biomarkers for investigation, each of which
has their own strengths and weaknesses. Discussion of each of
the individual markers can be found elsewhere in the litera-
ture.18–20 Many are associated with the metabolism of collagen
in cartilage (type II collagen) or subchondral bone (type I colla-
gen) or the metabolism of aggrecan in cartilage. Together, type
II collagen and aggrecan constitute the most abundant proteins
in the cartilage matrix, making them promising targets for
research. In addition, there are biomarkers related to a range of
non-collagenous proteins that have a role in other metabolic
pathways in the joint, including glycoproteins, proteoglycans,
metalloproteinases and advanced glycation endproducts, as well
as hyaluronan, which is a constituent of both cartilage and syno-
vium. Finally, there are a number of biomarkers associated with
other processes, such as inﬂammation or ﬁbrosis.
POTENTIAL VALUE OF BIOMARKERS IN OSTEOARTHRITIS
Biomarkers in osteoarthritis can be categorised using the ﬁve-
point burden of disease, investigative, prognostic, efﬁcacy of
intervention and diagnostic (BIPED) classiﬁcation scheme, which
was developed by the Osteoarthritis Biomarkers Network with
the aim of providing a common framework for communication
in the ﬁeld.21 Thus, a ‘diagnostic’ biomarker can distinguish
between individuals with and without osteoarthritis with good
positive and negative likelihood ratios (sensitivity and speciﬁcity)
and area under the curve in the receiving operator curve. A
‘burden of disease’ biomarker assesses disease severity in indivi-
duals with osteoarthritis, while a ‘prognostic’ biomarker predicts
Box 1 Selected biomarkers currently being investigated
for the evaluation of osteoarthritis.10–20
Biomarkers related to collagen metabolism
▸ C-terminal telopeptide of collagen type II (CTX-II)
▸ Type II collagen α chains collagenase neoepitope (α-CTX-II)
▸ Type II collagen propeptides (PIINP, PIIANP, PIIBNP, PIICP,
CPII)
▸ Pyridinoline and Glc-Gal-PYD
▸ Type II collagen cleavage product (C2C)
▸ Collagen type II-speciﬁc neoepitope (C2M)
▸ C-terminal telopeptide of collagen type I (CTX-I, α-CTX-I)
▸ N-terminal telopeptide of collagen type I (NTX-I)
▸ Aminoterminal propeptide of collagen type I (PINP)
▸ Types I and II collagen cleavage neoepitope (C1,C2)
Biomarkers related to aggrecan metabolism
▸ Core protein fragments (aggrecan neoepitopes, ARGS and
FFGV fragments)
▸ Chondroitin sulfate epitope 846 and monoclonal antibody
3B3(–)
▸ Keratan sulfate
Biomarkers related to other non-collagenous proteins
▸ Cartilage oligomeric matrix proteins (COMP and its
deamidated form D-COMP)
▸ Fibulin (peptides of ﬁbulin 3, Fib3-1, Fib3-2)
▸ Follistatin-like protein 1 (FSTL-1)
▸ Hyaluronan (hyaluronic acid)
▸ Matrix metalloproteinases (MMP-1, MMP-3, MMP-9,
MMP-13 and TIMPs)
▸ YKL-40 (cartilage glycoprotein 39)
▸ Soluble receptor for advanced glycation endproducts
(sRAGE)
Biomarkers related to other processes
▸ Inﬂammatory biomarkers: hs-CRP, IL-1β and IL-6 and COX-2
▸ Factors indicating ﬁbrosis and complement proteins
▸ Adipokines (adiponectin, leptin, visfatin)
▸ Soluble receptor for leptin (sOB-Rb)
▸ Cellular interactions in bone (periostin)
▸ Wnt inhibitors (DKKs and SOST)
▸ Uric acid
COMP, cartilage oligomeric protein; COX-2, cyclo-oxygenase-2;
Glc-Gal-PYD, glucosyl–galactosyl–pyridinoline; hs-CRP, high
sensitivity C reactive protein; IL, interleukin; MMP, matrix
metalloproteinase; PIIANP, N-propeptide IIA of type II collagen;
PIIBNP, N-propeptide IIB of type II collagen; PIICP, C-propeptide
of collagen type II; PIINP, N-propeptide II of type II collagen;
SOST, sclerostin; TIMP, tissue inhibitor of matrix
metalloproteinase.
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the onset of osteoarthritis in those without the disease or the pro-
gression of osteoarthritis in those with existing disease.
Prognostic biomarkers may be used to determine risk in those
without overt disease, clinical outcomes in patients with signs or
symptoms of osteoarthritis or the efﬁcacy of potential treatments
(ie, in drug development). Biomarkers for the ‘efﬁcacy of inter-
vention’ are those that can be applied in randomised controlled
trials to assess the short-term or long-term changes associated
with pharmacological treatments. Finally, BIPED classiﬁes
biomarkers as ‘investigative’ if there is insufﬁcient evidence to
classify promising candidates into one of the other categories.
A sixth category was added later to include the notion of ‘safety’,
updating the acronym to burden of disease, investigative, prog-
nostic, efﬁcacy of intervention, diagnostic, and safety
(BIPEDS).10 22 Safety is an important consideration for more
invasive investigations (eg, exposure to drugs, radiation or con-
trast agents).10 22 23 Similar frameworks for the categorisation of
biomarkers exist in other ﬁelds of medicine.5 24 The aim of the
BIPEDS classiﬁcation, designed speciﬁcally for osteoarthritis but
also applicable to other diseases, was to help capture information
in the early stages of development of the disease to inform the
design of future clinical trials and research in osteoarthritis.21
Classiﬁcation (using BIPED) was applied in a systematic
review of the literature in biomarkers in osteoarthritis, which
identiﬁed 84 relevant publications covering 26 different biomar-
kers published up to 2010.20 22 A systematic review of the lit-
erature is beyond the scope of this ESCEO paper, but for each
of the different categories of biomarkers we provide a few illus-
trative examples below.
Diagnostic biomarkers
Diagnostic biomarkers ideally identify patients at the stage of
osteoarthritis where treatment may be most effective. Although
there have been a number of promising studies in this direction,
no single biomarker stands out for use in diagnosis. A cross-
sectional study in 67 patients with knee osteoarthritis and 67
healthy controls tested the clinical performance of a range of 10
biomarkers sampled in serum and urine. Most of the biomarkers
of cartilage and synovium were signiﬁcantly different from con-
trols in the osteoarthritis patients (p<0.05 for eight of the bio-
markers tested). Urinary C-terminal telopeptide of collagen type
II (CTX-II), urinary Glc-Gal-Pyd and serum N-propeptide II of
type II collagen (PIINP), all of which were increased in patients
with osteoarthritis, were noted as potentially useful biomarkers
for the presence of osteoarthritis since they also correlated with
joint surface area.25 However, there was a substantial overlap
for all of the biomarkers tested between the patients and con-
trols. A study in 142 patients with osteoarthritis and 145
healthy controls supported the diagnostic potential of urinary
CTX-II, although it also reported that an aggregate score com-
bining CTX-II with imaging parameters had the best diagnostic
potential.26 Serum levels of cartilage oligomeric protein
(COMP) and type II collagen cleavage product (C2C) have also
been shown to correlate with knee degeneration in patients with
symptomatic knee osteoarthritis.27
Other candidates for diagnostic biomarkers have been identi-
ﬁed, with results for follistatin-like protein-1 (FSTL-1) in 42
osteoarthritis patients compared with six controls and also for
peptides of ﬁbulin 3 (Fib3), Fib3-1 and Fib3-2.28 In another
study, the cartilage synthesis product N-propeptide IIA of type
II collagen (PIIANP) was reported to be decreased in 43 patients
with knee osteoarthritis compared with 88 healthy controls.29
The presence of aggrecan neoepitopes was also shown to be
associated with the presence of osteoarthritis.30 Future possible
candidate diagnostic biomarkers include sRAGE, the plasma
levels of which were signiﬁcantly lower in 36 patients with knee
osteoarthritis than in 15 healthy controls (p<0.01),31 and the
presence of the glycoprotein YKL-40 in synovium or cartilage,
which is known to correlate with the presence of osteoarthritis
and disease severity32 and was demonstrated to be elevated in
patients with osteoarthritis versus healthy controls.33 Factors
indicating ﬁbrosis and complement proteins also play a role in
the pathogenesis of osteoarthritis and may prove to be useful
diagnostic biomarkers.34
Figure 1 Sources of possible
biomarkers in osteoarthritis.10–20 C2C,
cleavage of type II collagen; C2M,
collagen type II-speciﬁc neoepitope;
C3M, collagen type III-speciﬁc
neoepitope; Coll 2-1, 9-amino acid
peptide of type II collagen (nitrated form
Coll 2-1 NO2); COMP, cartilage
oligomeric protein; CPII, type II collagen
propeptide; CRP, C reactive protein; CTX,
C-terminal telopeptide of collagen; DKK,
wnt inhibitor; FSTL-1, follistatin-like
protein 1; ICTP, type I collagen-derived
cross-linked carboxy-terminal
telopeptide; IL, interleukin; MMP, matrix
metalloproteinase; NTX, N-terminal
telopeptide of collagen OPG,
osteoprotegerin; PIIANP, N-propeptide
IIA of type II collagen; PIIBNP,
N-propeptide IIB of type II collagen;
PIICP, C-propeptide of collagen
type II; PINP, N-propeptide of type I
collagen; PIINP, N-propeptide of type II
collagen; RANK-L, receptor activator of
nuclear factor κB ligand; RAGE, receptor
for advanced glycation endproducts;
TNF, tumour necrosis factor.
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Burden of disease biomarkers
The degradation product urinary CTX-II correlates well with
the presence of osteophytes upon radiography in most joints
affected by osteoarthritis and may be a sensitive quantitative bio-
marker for the severity of osteoarthritis.35 36 α-CTX-II has been
shown to reﬂect accelerated bone turnover in knee
osteoarthritis.37
As regards biomarkers unrelated to collagen, studies in 141
subjects with knee osteoarthritis showed that levels of synovial
ﬂuid aggrecan fragments can differentiate between mild and
moderate osteoarthritis in terms of radiographic JSN, as well as
pain and function (patient-reported outcomes).38 COMP is also
promising in the evaluation of the severity of knee osteoarth-
ritis,39 40 as is the level of uric acid in synovial ﬂuid.41
The relationship between the levels of three biomarkers
(urinary CTX-II, serum COMP and serum hyaluronan) and
radiographic features in various joints (hand, hip, knee and
lumbar spine) was explored in a study in 461 women originally
recruited on the basis of hand osteoarthritis.36 The results
showed differences between the biomarkers in terms of correla-
tions with radiographic indices of osteoarthritis. Although there
were positive correlations between the number of joints affected
by osteophytes and CTX-II (R2=0.51), COMP (R2=0.47) and
hyaluronan (R2=0.51), there was no correlation (upon adjust-
ment for the presence of osteophytes) between the number of
joints with JSN for CTX-II (R2=0.01) or hyaluronan (R2=0.05)
and a negative correlation for COMP (R2=0.69).36 The native
form of COMP (without post-translational deamidation of the
amino-terminus) was found to be more speciﬁc for knee osteo-
arthritis, while the deamidated form of COMP (D-COMP) was
found to be more speciﬁc for hip osteoarthritis than for knee.42
This indicates that some molecules may be more powerful bio-
markers in speciﬁc joints.43 On the other hand, the high correl-
ation between serum COMP and age and the observed high
heritability of the marker43 44 imply that the marker may have
an innate, systemic value independent of the joint site with
osteoarthritis, which could hamper the association.
A number of studies have revealed links between adipokines
(adiponectin, leptin and visfatin) and joint disease. While these
proinﬂammatory cytokines are generally produced by white
adipose tissue, they are also expressed by osteoblasts, synovio-
cytes and chondrocytes45–47 and have been described as import-
ant elements in joint inﬂammation and extracellular matrix
degradation.45 48 49 High levels of adiponectin and leptin have
been measured in synovial ﬂuid of patients with osteoarthritis
and were reported to correlate with the severity of
osteoarthritis.50 51
Prognostic biomarkers
Elevated levels of urinary CTX-II have been demonstrated to be
associated with radiographic progression.26 52 In a study in
1235 men and women participating in the Rotterdam study,
those with urinary CTX-II levels in the highest quartile were at
six times higher risk for radiographic progression of knee osteo-
arthritis (OR 6.0, 95% CI 1.2 to 30.8) and more than eight
times higher risk for progression of hip osteoarthritis (OR, 8.4,
95% CI 1.0 to 72.9).52 These results were independent of
known clinical risk factors for osteoarthritis, such as age, sex
and body mass index. Similarly, CTX-II was shown to predict
cartilage loss by MRI, and in addition to MRI modalities, to
provide an OR of more than 10 for identiﬁcation of progres-
sors.26 53 In this context, and as mentioned above, data suggest
that CTX-II may be more a marker of bone turnover than
cartilage breakdown,54 although further research is necessary to
assess whether this association is based on confounding of bone
turnover with the osteoarthritis process or is actually causally
related due to cross-reactivity of the epitope. There have also
been promising results for prognosis with serum COMP and
urinary CTX-II in a cohort of patients with knee osteoarth-
ritis.55 In a community-based cohort of 800 individuals, high
levels of serum COMP and hyaluronan were reported to predict
incident knee osteoarthritis and symptoms over a follow-up
period of 6 years (HR for incident JSN with 1 unit higher
ln(COMP), 1.82 (95% CI 1.15 to 2.89) and with 1 unit higher
ln(hyaluronan), 1.46 (95% CI 1.14 to 1.87)).56 Finally, a study
in 161 patients with knee osteoarthritis showed that levels of
the matrix metalloproteinases MMP-1 and MMP-3 were pre-
dictive of cartilage volume loss as evaluated by quantitative MRI
over 2 years (both p<0.05).57 Insofar as the relationship
between cartilage biomarkers and cartilage volume loss is not
linear across populations, biomarkers may prove useful to select
subgroups among which osteoarthritis progresses at different
rates.58
As regards preradiographic osteoarthritis, collagen type
II-speciﬁc neoepitope59 (C2M) and C2C have been found to be
promising for the prediction of cartilage loss, especially when
the ratio of the two biomarkers, which is increased with the
onset of osteoarthritis, is considered.60 This suggests that panels
of biomarkers may be a better choice for predicting outcomes.
Adiponectin, visfatin, leptin and leptin’s soluble receptor
(OB-Rb) are increased in blood samples from patients with
osteoarthritis61 62 and have been correlated with disease pro-
gression in hand osteoarthritis,63 cartilage volume loss in knee
osteoarthritis64 and radiographic changes in hip osteoarthritis.65
The presence of inﬂammatory biomarkers has also been
shown to predict outcomes in osteoarthritis. Elevated high sensi-
tivity C reactive protein (hs-CRP) predicts cartilage loss asso-
ciated with osteoarthritis, as well as poorer outcomes after total
knee joint replacement.57 66 67 Similar effects have also been
found for interleukin 6 (IL-6).57 68 On the other hand, the spe-
ciﬁcity of inﬂammatory biomarkers for osteoarthritis may be
limited since they are implicated in a range of inﬂammatory
conditions and the utility and signiﬁcance of hs-CRP are gener-
ally limited in osteoarthritis when body mass index is taken into
account.
Efﬁcacy of intervention
There have been a number of studies linking the efﬁcacy of
interventions in osteoarthritis to levels of urinary CTX-II.20 The
use of biomarkers for efﬁcacy of intervention has been consider-
ably limited by the absence of proven DMOADs, and most
agents used in osteoarthritis have given rather inconsistent
results with various biomarkers. Strontium ranelate has recently
been shown to have DMOAD properties,69 and so further ana-
lysis of these trial results may be expected to shed more light on
this issue.
Investigative biomarkers
Advances in ‘omics’ research are uncovering a range of new can-
didate biomarkers. Although only some of the data have been
validated independently, this is a ﬁeld of active research and of
major importance in osteoarthritis. For the genetic component
of risk for osteoarthritis, a number of genetic polymorphisms
related to cartilage breakdown have been identiﬁed.70 71 A large
genome-wide association study identiﬁed eight novel genetic
risk loci for osteoarthritis, revealing new pathways for explor-
ation for potential biomarkers.72 Interestingly, this study also
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found that the risk loci were generally speciﬁc to the hip or the
knee, indicating joint-speciﬁc disease pathways. Of note, genetic
studies are bound to provide insight into new aetiological routes
to osteoarthritis. Such insights may eventually provide new bio-
markers. However, the effect sizes of the genetic markers are
very small and so there is little chance that the genetic marker
itself may be powerful as a biomarker. Metabolomics studies are
also promising to identify novel serum biomarkers in osteoarth-
ritis, such as the ratio between branched chain amino acids and
histidine.73 74 As the number of testable metabolites moves from
small numbers towards several thousands, more biomarkers are
likely to emerge from these improving technologies.75
Proteomic analyses are also likely to produce novel biomarkers,
for example, one study detected four new potential biomarkers
that correlated with parameters of inﬂammation, bone remodel-
ling, and cartilage turnover.76 Recent proteomics studies are also
in line with pronounced differences between cartilage from dif-
ferent joint sites.77 These results also support known differences
in clinical progression in a speciﬁc joint (eg, progressive hand
osteoarthritis). Finally, research in lipidomics suggests altered
lipid metabolism in osteoarthritis, which may also be a source of
novel biomarkers.78
DISCUSSION
None of the current biomarkers is sufﬁciently discriminating to
aid the diagnosis of osteoarthritis or aid the prognosis of indivi-
duals with or without the disease or performs so consistently
that it could function as a surrogate outcome in clinical trials as
a secondary or supportive endpoint. The ESCEO group identi-
ﬁed a number of possible avenues for future research in the ﬁeld
(box 2), some of which are necessary before biomarkers can
enter routine clinical use for monitoring disease activity or in
drug development for the measurement of response to treat-
ment in osteoarthritis. The arrival of new DMOADs may help
better deﬁne biomarkers in osteoarthritis.
Despite this, there are a few very promising candidates. The
most promising are biomarkers of cartilage metabolism,
although biomarkers of synovial tissue degradation may also
prove to be useful in future. In this context, studies of the syn-
ovial ﬂuid proteome have explored the contribution of innate
immunity and the complement cascade.34 79 80 The results
suggest a major contribution of synovial gene products to the
osteoarthritis synovial proteome.80 A systematic review applying
the BIPED classiﬁcation indicated that urinary CTX-II and
serum COMP appear to have the best performance of all com-
mercially available biomarkers.20 On the other hand, the same
review also highlighted a general lack of consistent evidence, dif-
ferences between the populations studied (clinical trial popula-
tions vs population-based cohorts), differences in sample
collection and possibly publication bias.20 Thus, future research
efforts should be made to validate the existing markers and
identify new candidates (box 2). Such research should involve
further exploration of the underlying mechanisms of disease.
The ongoing head-to-head comparison of a large panel of bio-
markers (a dozen biochemical biomarkers and multiple sensitive
imaging biomarkers) through the OARSI/Foundation for NIH
study promises to provide much needed vital information for
determining some of the best candidates for further qualiﬁcation
in clinical trial scenarios.81
Interestingly, the biomarkers with the most consistent evi-
dence appear to be those at the end of the pathways of tissue
destruction, which may be more speciﬁc for a particular tissue
(eg, CTX-II). In this context, there is evidence that there may be
differences in some biomarkers between different joints or
tissues,42 43 77 and there are indications of differences in rela-
tion to distance from the surface of the joint.82
The use of biomarkers in drug development in osteoarthritis
remains a subject of research. The ESCEO group noted the dif-
ferences with the ﬁeld of osteoporosis, for which the use of bio-
markers is much better established. This is principally due to the
magnitude of clinical advances in osteoporosis in the last
20 years, for which there is now a range of disease-modifying
treatments, in comparison with osteoarthritis, for which
DMOADs are only just beginning to appear with the need to
sufﬁciently justify their efﬁcacy and safety to use them in bio-
marker development or research.69 Another point is that the
amount of bone mass involved in bone turnover of a joint is
much larger than the small amount of cartilage available in the
joints; this suggests that the systemic biomarker contribution
due to localised high bone turnover at a speciﬁc osteoarthritic
joint might be more readily detected than the contribution due
to high cartilage turnover of the joint. However, in all cases, the
biomarker contributions from local disease need to be distin-
guished from the contributions of normal bone and cartilage
turnover; this is currently a primary limitation for all systemic
(serum and urine) biomarker measures. For use in Phase II or
dose-ﬁnding studies, biomarkers should be able to predict struc-
tural change. In Phase III, they should predict more concrete
endpoints, such as surgery, or indeed play an explanatory role in
terms of mechanism of action. In this context, there is still
much discussion in the osteoarthritis ﬁeld regarding hard end-
points, since joint replacement is affected by a number of
factors unrelated to efﬁcacy of treatment (eg, patient preference,
access to healthcare, individual variations in pain and symp-
toms). Surrogate endpoints for joint replacement have been
developed, such as virtual joint replacement,83 although consen-
sus has not been reached in the ﬁeld and the potential role of
biomarkers remains to be deﬁned. Moreover, there is currently
no hard evidence that improving structure ( JSN or cartilage
Box 2 Avenues for future research in biomarkers in
osteoarthritis
Mechanisms of disease/development of new biomarkers
▸ Research into the underlying mechanisms of disease to
validate existing biomarkers and identify new candidates
▸ Research into biomarkers from ‘omics’
▸ Identiﬁcation of differences in effects of biomarkers between
joints (knee, hip, hand, spine, etc) to explore whether there
are speciﬁc biomarkers for speciﬁc joints
Assays and technological development
▸ Improved assays/technologies
▸ Standardisation/calibration of biomarkers
▸ Development of aggregate scores combining a panel of
known (conﬁrmed) biomarkers (with or without imaging
markers) into single diagnostic tests
Prognosis and risk
▸ Improvement of the deﬁnition of early osteoarthritis
▸ Identiﬁcation of biomarkers for early stages of osteoarthritis
(preradiographic)
▸ Further studies on correlations between changes in
biomarkers and hard clinical endpoints (eg, joint
replacement or virtual joint replacement)
▸ Research to place biomarkers within the assessment of risk
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volume loss) improves symptoms (pain and function) in
osteoarthritis.
One theoretical advantage of biomarkers in all ﬁelds of medi-
cine is the detection of the early phases of disease. The ability
to detect early stage osteoarthritis would not only improve the
management of patients via preventative measures and lifestyle
changes, but may also facilitate efforts in drug development by
improving the design of randomised clinical trials. Many bio-
logical markers appear to be sufﬁciently characterised for the
study of progressive osteoarthritis, but few have been identiﬁed
for the diagnosis of the early stage of the disease. Moreover,
early osteoarthritis has not been clearly deﬁned. This is an
important avenue for future research (box 2).
The ability to predict the onset or progression of disease is an
important feature of biomarker research since it will have impli-
cations in clinical medicine. In this context, clinicians need
reassurance that the biomarkers truly represent clinical out-
comes (ie, structural damage). Indeed, predictive value is essen-
tial to determine which patients are likely to progress rapidly
and, ideally, which patients are likely to respond to treatment.
A biomarker that characterises risk for generalised disease
should have broad utility. A related issue is the role of biomar-
kers in the context of risk factors and their assessment.
There is increasing evidence that the best solution may be a
panel of biomarkers, covering the range of physiological effects,
or indeed a combination of tissue biomarkers with other para-
meters (eg, radiographic or MRI) into single diagnostic
tests.43 84 An analysis of a set of 14 biomarkers in a cohort of
1002 individuals with early osteoarthritis (Cohort Hip and
Cohort Knee) suggested the possibility of clusters of biomarkers
related to speciﬁc pathogenic processes, for example, cartilage
synthesis, synovium or inﬂammation.84 Recognising such under-
lying patterns may increase prognostic accuracy and predictive
power, thus enabling better identiﬁcation of at-risk patients;
further research is essential (box 2).
A well-selected panel of biomarkers may also assist in identify-
ing the patients who are most likely to respond (personalised
medicine). In theory, targeting responders would reduce the cost
of treatment on the population level by eliminating redundant
prescriptions and improving beneﬁts for patients. The ideal
panel should include, for example, biomarkers of turnover, syn-
thesis and degradation and tissue-speciﬁc biomarkers (cartilage,
subchondral bone and inﬂammation). Ratios of speciﬁc biomar-
kers may also prove to be important.60
There are a number of major research limitations that need to
be addressed in the ﬁeld of biomarkers. One of these is the
rarity of DMOADs, which has hindered research to ﬁnd a valid
biochemical marker. There are many potential errors in bio-
marker analysis related to sampling, biological variations (eg,
seasonal, diurnal and food intake), analyte features, assay format
and parameters,19 which can confound results. These should be
resolved by further research in assays and technological develop-
ment, as well as standardisation and calibration of known bio-
markers and optimisation of data collection (box 2). Another
limitation is the non-linear relationship between biomarkers and
some structural parameters,58 which will complicate the devel-
opment of prognostic biomarkers. In addition, the identiﬁcation
of patients is complicated since the pathways to a failed joint
may involve many different mechanisms (eg, bone-active treat-
ments work in some patients and anti-inﬂammatories in others).
Another limitation is the relationship between osteoarthritis bio-
markers and ‘normal’ age-related processes independent of the
osteoarthritis process, which is not well deﬁned.85
CONCLUSION
The conclusion of the ESCEO working group was that there is a
potential role for biomarkers in drug development in osteoarth-
ritis. However, none of the best candidate biomarkers has
entered clinical use. For the moment, radiographic measure-
ments combined with pain and function remain the regulatory
endpoint in DMOAD development.2 3 Radiographic data may
be supplanted by MRI markers in future, although there is still
work to be done to reach a consensus on which MRI para-
meters are the most relevant. While biomarkers are not likely to
constitute the ideal primary endpoint, they could be valuable
secondary endpoints in future drug development because they
provide evidence of pharmacodynamics and mechanisms of
action, support the primary endpoint and can help identify sub-
groups. There remains a clear need for more research in the
ﬁeld.
Author afﬁliations
1Department of Molecular and Experimental Medicine, The Scripps Research
Institute, La Jolla, California, USA
2Osteoarthritis Research Unit, University of Montreal Hospital Research Centre
(CRCHUM), Montreal, Quebec, Canada
3Nordic Bioscience A/S, Herlev, Denmark
4Metabolic Bone Unit, Department of Internal Medicine, University of Florence,
Florence, Italy
5Department of Public Health, Epidemiology and Health Economics, University of
Liège, Liège, Belgium
6INSERM UMR 1033 and Université de Lyon, Service de Rhumatologie et Pathologie
Osseuse, Hôpital Edouard Herriot, Lyon, France
7Department of Clinical Chemistry, Bone and Cartilage Markers Laboratory, CHU,
University of Liège, Liège, Belgium
8MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
9NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK
10Clinical Research Unit, Rottapharm Madaus Group, Monza, Italy
11WHO Collaborating Centre for Metabolic Bone Diseases, University of Shefﬁeld
Medical School, Shefﬁeld, UK
12Division of Rheumatology, Department of Medicine, Duke University School of
Medicine, Durham, North Carolina, USA
13Department of Rheumatology, VU University Medical Centre, Amsterdam, The
Netherlands
14Leiden University Medical Centre, Section of Molecular Epidemiology, Leiden, The
Netherlands
15Federal Institute for Drugs and Medical Devices (BfArM), Bonn, Germany
16Division of Bone Diseases, Geneva University Hospital and Faculty of Medicine,
Geneva, Switzerland
17Department of Cell Biology and Physiology, Washington University, St Louis,
Missouri, USA
18Department of Rheumatology and Clinical immunology, University Medical Center
Utrecht, Utrecht, The Netherlands
19Bone and Cartilage Metabolism Research Unit and Department of Public Health
Sciences, CHU Centre-Ville, Policliniques L. Brull, University of Liège, Liège, Belgium
Correction notice This article has been corrected since it was published Online
First. Fig 1 has been corrected and minor textual changes made.
Acknowledgements We thank Professor Tim Spector for valuable input during
the preparation of this manuscript.
Contributors All authors participated in preparing the manuscript and approved its
ﬁnal version.
Competing interests M-LB: support from Fondazione Fondazione Italiana Ricerca
Malattie Ossee (F.I.R.M.O.) and grants from Merck Sharpe & Dohme, Nycomed,
Roche, Glaxo, Eli Lilly and Wyeth. Speaker fees from Procter and Gamble, Merck
Sharpe & Dohme, Nycomed and Wyeth. OB: grant research: GlaxoSmithKline, IBSA,
Merck Sharp & Dohme, Theramex, Novartis, Pﬁzer, Rottapharm and Servier;
consulting or lecture fees: IBSA, Rottapharm, Servier; reimbursement for attending
meetings: IBSA, Merck Sharp & Dohme, Novartis, Pﬁzer, Rottapharm, Theramex and
Servier. RC: research grants: Merck, Chugai-Roche and Warner-Chilcott; consulting
and/or lecture fees: Servier, Chugai-Roche, Novartis, Amgen, Pﬁzer, UCB and
Bioiberica. CC: consulting fees, paid advisory boards, lecture fees and/or grant
support from Roche, Wyeth-Ayerst, Eli Lilly, Novartis, Novo Nordisk, Proctor and
Gamble, Groupe Fournier, Besins EscoVesco, MSD, Chiesi, Boehringer Mannheim,
Pﬁzer and Servier. Chairman of Nordic Bioscience A/S and Chairman of CCBR/
Synarc. JC: None. CC: consulting fees and paid advisory boards for Alliance for
Lotz M, et al. Ann Rheum Dis 2013;72:1756–1763. doi:10.1136/annrheumdis-2013-203726 1761
Review
group.bmj.com on July 26, 2017 - Published by http://ard.bmj.com/Downloaded from 
Better Bone Health, Glaxo Smith Kline, Roche, Merck Sharp and Dohme, Lilly,
Amgen, Wyeth, Novartis, Servier and Nycomed. GG: None. JAK: consulting fees,
paid advisory boards, lecture fees and/or grant support from the majority of
companies concerned with skeletal metabolism. MAK: employee of Nordic
Bioscience. VK: grant support from Bioiberica. WFL: speaker fees and paid advisory
boards from Pﬁzer, Servier, Merck, Amgen, Novartis, Will Pharma, Procter &
Gamble, Abbott, Roche and Lilly. ML: grant support from Cargill and paid advisory
board from Tanabe Research Laboratories. JM-P: owner, ArthroLab Inc. Consulting
fees from AstraZeneca, Bioibérica, Boehringer Ingelheim, Elanco, Ferring, Merck,
Pﬁzer, Servier, TRB Chemedica and Virbac. IM: none. J-PP: owner, ArthroLab Inc.
Consulting fees from AstraZeneca, Bioibérica, Boehringer Ingelheim, Elanco, Ferring,
Merck, Pﬁzer, Servier, TRB Chemedica and Virbac. J-PR: consulting fees and lecture
fees from AbbVie, Pﬁzer, Servier, Novartis, Lilly, Amgen, GlaxoSmithKline, Roche,
UCB, Merck and Bristol Myers Squibb. J-YR: consulting fees, paid advisory boards,
lecture fees and/or grant support from Servier, Novartis, Negma, Lilly, Wyeth,
Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex, UCB, Merck
Sharp and Dohme, Rottapharm, IBSA, Genevrier, Teijin, Teva, Ebewee Pharma,
Zodiac, Analis, Novo-Nordisk and Bristol Myers Squibb. SR-N: none. RR: consulting
and lecture fees for Merck Sharp and Dohme, Eli Lilly, Amgen, Novartis, Servier,
Nycomed, Nestlé and Danone. LS: none. WEVS: none.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/3.0/
REFERENCES
1 Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for
clinical practice. Lancet 2011;377:2115–26.
2 Committee for Medicinal Products for Human Use. Guideline on clinical
investigation of medicinal products used in the treatment of osteoarthritis. 2010.
http://www.ema.europa.eu (accessed 19 Sept 2012).
3 Food and Drug Administration. Guidance for industry. Clinical development
programs for drugs, devices, and biological products intended for the treatment of
osteoarthritis. 2011. http://www.fda.gov (accessed 12 Jun 2012).
4 Hunter DJ, Guermazi A. Imaging techniques in osteoarthritis. PM&R 2012;4:
S68–74.
5 Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers Deﬁnitions Working
Group. Biomarkers and surrogate endpoints: preferred deﬁnitions and conceptual
framework. Clin Pharmacol Ther 2001;69:89–95.
6 Iagnocco A, Perricone C, Scirocco C, et al. The interobserver reliability of ultrasound
in knee osteoarthritis. Rheumatology (Oxford) 2012;51:2013–19.
7 Eckstein F, Wirth W. Quantitative cartilage imaging in knee osteoarthritis. Arthritis
2011;2011:475684.
8 Pelletier JP, Cooper C, Peterfy C, et al. What is the predictive value of MRI for the
occurrence of knee replacement surgery in knee osteoarthritis? Ann Rheum Dies
2013;72:1594–604.
9 Scanzello CR, Plaas A, Crow MK. Innate immune system activation in osteoarthritis:
is osteoarthritis a chronic wound? Cur Open Rheumatic 2008;20:565–72.
10 Kraus VB, Burnett B, Coindreau J, et al. Application of biomarkers in the
development of drugs intended for the treatment of osteoarthritis. Osteoarthritis
Cartilage 2011;19:515–42.
11 Rousseau JC, Garnero P. OARSI Primer. Chapter 10. Biochemical markers. 2010.
http://primer.oarsi.org (accessed 6 Nov 2012).
12 Charni-Ben TN, Garnero P. Monitoring cartilage turnover. Cur Rheumatic Rep
2007;9:16–24.
13 Mobasheri A. Osteoarthritis year 2012 in review: biomarkers. Osteoarthritis
Cartilage 2012;20:1451–64.
14 Rousseau JC, Garnero P. Biological markers in osteoarthritis. Bone
2012;51:265–77.
15 Williams FM, Spector TD. Biomarkers in osteoarthritis. Arthritis Res Ther
2008;10:101.
16 Rousseau JC, Delmas PD. Biological markers in osteoarthritis. Nat Clin Pract
Rheumatic 2007;3:346–56.
17 Karsdal MA, Madsen SH, Christiansen C, et al. Cartilage degradation is fully
reversible in the presence of aggrecanase but not matrix metalloproteinase activity.
Arthritis Res Ther 2008;10:R63.
18 Karsdal MA, Nielsen MJ, Sand JM, et al. Extracellular matrix remodeling: the
common denominator in connective tissue diseases possibilities for evaluation and
current understanding of the matrix as more than a passive architecture, but a key
player in tissue failure. Assay Drug Dev Technol 2013;11:70–92.
19 Karsdal MA, Woodworth T, Henriksen K, et al. Biochemical markers of ongoing
joint damage in rheumatoid arthritis—current and future applications, limitations
and opportunities. Arthritis Res Ther 2011;13:215.
20 van Spil WE, Degroot J, Lems WF, et al. Serum and urinary biochemical markers for
knee and hip-osteoarthritis: a systematic review applying the consensus BIPED
criteria. Osteoarthritis Cartilage 2010;18:605–12.
21 Bauer DC, Hunter DJ, Abramson SB, et al. Classiﬁcation of osteoarthritis
biomarkers: a proposed approach. Osteoarthritis Cartilage 2006;14:723–7.
22 Kraus VB. Osteoarthritis year 2010 in review: biochemical markers. Osteoarthritis
Cartilage 2011;19:346–53.
23 Kraus VB, Nevitt M, Sandell LJ. Summary of the OA biomarkers workshop 2009—
biochemical biomarkers: biology, validation, and clinical studies. Osteoarthritis
Cartilage 2010;18:742–5.
24 Jain KK. The handbook of biomarkers. New York, NY: Springer, 2010.
25 Garnero P, Piperno M, Gineyts E, et al. Cross sectional evaluation of biochemical
markers of bone, cartilage, and synovial tissue metabolism in patients with knee
osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dies
2001;60:619–26.
26 Dam EB, Loog M, Christiansen C, et al. Identiﬁcation of progressors in osteoarthritis
by combining biochemical and MRI-based markers. Arthritis Res Ther 2009;11:
R115.
27 King KB, Lindsey CT, Dunn TC, et al. A study of the relationship between molecular
biomarkers of joint degeneration and the magnetic resonance-measured
characteristics of cartilage in 16 symptomatic knees. Magn Reson Imaging
2004;22:1117–23.
28 Wang Y, Li D, Xu N, et al. Follistatin-like protein 1: a serum biochemical marker
reﬂecting the severity of joint damage in patients with osteoarthritis. Arthritis Res
Ther 2011;13:R193.
29 Rousseau JC, Zhu Y, Miossec P, et al. Serum levels of type IIA procollagen amino
terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and
rheumatoid arthritis. Osteoarthritis Cartilage 2004;12:440–7.
30 Duﬁeld DR, Nemirovskiy OV, Jennings MG, et al. An immunoafﬁnity liquid
chromatography-tandem mass spectrometry assay for detection of endogenous
aggrecan fragments in biological ﬂuids: use as a biomarker for aggrecanase activity
and cartilage degradation. Anal Biochem 2010;406:113–23.
31 Chayanupatkul M, Honsawek S. Soluble receptor for advanced glycation end
products (sRAGE) in plasma and synovial ﬂuid is inversely associated with disease
severity of knee osteoarthritis. Clin Biochem 2010;43:1133–7.
32 Huang K, Wu LD. YKL-40: a potential biomarker for osteoarthritis. J Int Med Res
2009;37:18–24.
33 Johansen JS, Hvolris J, Hansen M, et al. Serum YKL-40 levels in healthy children
and adults. Comparison with serum and synovial ﬂuid levels of YKL-40 in patients
with osteoarthritis or trauma of the knee joint. Br J Rheumatic 1996;35:553–9.
34 Wang Q, Rozelle AL, Lepus CM, et al. Identiﬁcation of a central role for
complement in osteoarthritis. Nat Med 2011;17:1674–9.
35 Meulenbelt I, Kloppenburg M, Kroon HM, et al. Urinary CTX-II levels are associated
with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in
subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum
Dies 2006;65:360–5.
36 Kraus VB, Kepler TB, Stabler T, et al. First qualiﬁcation study of serum biomarkers
as indicators of total body burden of osteoarthritis. PLoS ONE 2010;5:e9739.
37 Huebner JL, Bay-Jensen AC, Leeming DJ, et al. Urinary markers,alpha CTX and
CTXII,are indicative of OA severity and bone turnover. Oral communication 048.
Osteoarthritis Cartilage 2010;18(Suppl 2):S29–30.
38 Larsson S, Englund M, Struglics A, et al. The association between changes in
synovial ﬂuid levels of ARGS-aggrecan fragments, progression of radiographic
osteoarthritis and self-reported outcomes: a cohort study. Osteoarthritis Cartilage
2012;20:388–95.
39 Clark AG, Jordan JM, Vilim V, et al. Serum cartilage oligomeric matrix protein
reﬂects osteoarthritis presence and severity: the Johnston County Osteoarthritis
Project. Arthritis Rheum 1999;42:2356–64.
40 Wislowska M, Jablonska B. Serum cartilage oligomeric matrix protein (COMP) in
rheumatoid arthritis and knee osteoarthritis. Clin Rheumatic 2005;24:278–84.
41 Denoble AE, Huffman KM, Stabler TV, et al. Uric acid is a danger signal of
increasing risk for osteoarthritis through inﬂammasome activation. Proc Natl Acad
Sci USA 2011;108:2088–93.
42 Catterall JB, Hsueh MF, Stabler TV, et al. Protein modiﬁcation by deamidation
indicates variations in joint extracellular matrix turnover. J Biol Chem
2012;287:4640–51.
43 Meulenbelt I, Kloppenburg M, Kroon HM, et al. Clusters of biochemical markers are
associated with radiographic subtypes of osteoarthritis (OA) in subject with familial
OA at multiple sites. The GARP study. Osteoarthritis Cartilage 2007;15:379–85.
44 Chen HC, Kraus VB, Li YJ, et al. Genome-wide linkage analysis of quantitative
biomarker traits of osteoarthritis in a large, multigenerational extended family.
Arthritis Rheum 2010;62:781–90.
45 Lago R, Gomez R, Otero M, et al. A new player in cartilage homeostasis:
adiponectin induces nitric oxide synthase type II and pro-inﬂammatory cytokines in
chondrocytes. Osteoarthritis Cartilage 2008;16:1101–9.
46 Lago F, Dieguez C, Gomez-Reino J, et al. The emerging role of adipokines as
mediators of inﬂammation and immune responses. Cytokine Growth Factor Rev
2007;18:313–25.
1762 Lotz M, et al. Ann Rheum Dis 2013;72:1756–1763. doi:10.1136/annrheumdis-2013-203726
Review
group.bmj.com on July 26, 2017 - Published by http://ard.bmj.com/Downloaded from 
47 Berner HS, Lyngstadaas SP, Spahr A, et al. Adiponectin and its receptors are
expressed in bone-forming cells. Bone 2004;35:842–9.
48 Gosset M, Berenbaum F, Salvat C, et al. Crucial role of visfatin/pre-B cell colony-
enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes:
possible inﬂuence on osteoarthritis. Arthritis Rheum 2008;58:1399–409.
49 Vuolteenaho K, Koskinen A, Kukkonen M, et al. Leptin enhances synthesis of
proinﬂammatory mediators in human osteoarthritic cartilage–mediator role of NO in
leptin-induced PGE2, IL-6, and IL-8 production. Mediators Inﬂamm
2009;2009:345838.
50 Ku JH, Lee CK, Joo BS, et al. Correlation of synovial ﬂuid leptin concentrations with
the severity of osteoarthritis. Clin Rheumatic 2009;28:1431–5.
51 Schafﬂer A, Ehling A, Neumann E, et al. Adipocytokines in synovial ﬂuid. JAMA
2003;290:1709–10.
52 Reijman M, Hazes JM, Bierma-Zeinstra SM, et al. A new marker for osteoarthritis:
cross-sectional and longitudinal approach. Arthritis Rheum 2004;50:2471–8.
53 Dam EB, Byrjalsen I, Karsdal MA, et al. Increased urinary excretion of
C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by
MRI. Osteoarthritis Cartilage 2009;17:384–9.
54 van Spil WE, Drossaers-Bakker KW, Lafeber FP. Associations of CTX-II with
biochemical markers of bone turnover raise questions on its tissue origin: data from
CHECK, a cohort study of early osteoarthritis. Ann Rheum Dies 2013;72:29–36.
55 Sowers MF, Karvonen-Gutierrez CA, Yosef M, et al. Longitudinal changes of serum
COMP and urinary CTX-II predict X-ray deﬁned knee osteoarthritis severity and
stiffness in women. Osteoarthritis Cartilage 2009;17:1609–14.
56 Golightly YM, Marshall SW, Kraus VB, et al. Biomarkers of incident radiographic
knee osteoarthritis: do they vary by chronic knee symptoms? Arthritis Rheum
2011;63:2276–83.
57 Pelletier JP, Raynauld JP, Caron J, et al. Decrease in serum level of matrix
metalloproteinases is predictive of the disease-modifying effect of osteoarthritis
drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann Rheum
Dies 2010;69:2095–101.
58 Berry PA, Maciewicz RA, Wluka AE, et al. Relationship of serum markers of
cartilage metabolism to imaging and clinical outcome measures of knee joint
structure. Ann Rheum Dies 2010;69:1816–22.
59 Bay-Jensen AC, Liu Q, Byrjalsen I, et al. Enzyme-linked immunosorbent assay
(ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM—increased
serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem
2011;44:423–9.
60 Ishijima M, Watari T, Naito K, et al. Relationships between biomarkers of cartilage,
bone, synovial metabolism and knee pain provide insights into the origins of pain in
early knee osteoarthritis. Arthritis Res Ther 2011;13:R22.
61 Chen WP, Bao JP, Feng J, et al. Increased serum concentrations of visfatin and its
production by different joint tissues in patients with osteoarthritis. Clin Chem Lab
Med 2010;48:1141–5.
62 Laurberg TB, Frystyk J, Ellingsen T, et al. Plasma adiponectin in patients with active,
early, and chronic rheumatoid arthritis who are steroid- and disease-modifying
antirheumatic drug-naive compared with patients with osteoarthritis and controls.
J Rheumatic 2009;36:1885–91.
63 Yusuf E, Ioan-Facsinay A, Bijsterbosch J, et al. Association between leptin,
adiponectin and resistin and long-term progression of hand osteoarthritis. Ann
Rheum Dies 2011;70:1282–4.
64 Berry PA, Jones SW, Cicuttini FM, et al. Temporal relationship between serum
adipokines, biomarkers of bone and cartilage turnover, and cartilage volume loss in
a population with clinical knee osteoarthritis. Arthritis Rheum 2011;63:700–7.
65 Stannus OP, Jones G, Quinn SJ, et al. The association between leptin, interleukin-6,
and hip radiographic osteoarthritis in older people: a cross-sectional study. Arthritis
Res Ther 2010;12:R95.
66 Smith JW, Martins TB, Gopez E, et al. Signiﬁcance of C-reactive protein in
osteoarthritis and total knee arthroplasty outcomes. Ther Adv Musculoskelet Dies
2012;4:315–25.
67 Sharif M, Shepstone L, Elson CJ, et al. Increased serum C reactive protein may
reﬂect events that precede radiographic progression in osteoarthritis of the knee.
Ann Rheum Dies 2000;59:71–4.
68 Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF-alpha are
associated with knee radiographic osteoarthritis and knee cartilage loss in older
adults. Osteoarthritis Cartilage 2010;18:1441–7.
69 Reginster J-Y, Badurski J, Bellamy N, et al. Efﬁcacy and safety of oral strontium
ranelate for the treatment of knee osteoarthritis: results of a randomised
double-blind, placebo-controlled trial. Ann Rheum Dies 2013;72:179–86.
70 Meulenbelt I, Kraus VB, Sandell LJ, et al. Summary of the OA biomarkers workshop
2. Osteoarthritis Cartilage 2011;19:1091–4.
71 Valdes AM, Loughlin J, Oene MV, et al. Sex and ethnic differences in the
association of ASPN, CALM1, COL2A1, COMP, and FRZB with genetic susceptibility
to osteoarthritis of the knee. Arthritis Rheum 2007;56:137–46.
72 Zeggini E, Panoutsopoulou K, Southam L, et al. Identiﬁcation of new susceptibility
loci for osteoarthritis (arcOGEN): a genome-wide association study. Lancet
2012;380:815–23.
73 Zhai G, Wang-Sattler R, Hart DJ, et al. Serum branched-chain amino acid to
histidine ratio: a novel metabolomic biomarker of knee osteoarthritis. Ann Rheum
Dies 2010;69:1227–31.
74 Adams SB Jr, Setton LA, Kensicki E, et al. Global metabolic proﬁling of human
osteoarthritic synovium. Osteoarthritis Cartilage 2012;20:64–7.
75 Suhre K, Shin SY, Petersen AK, et al. Human metabolic individuality in biomedical
and pharmaceutical research. Nature 2011;477:54–60.
76 de Seny D, Sharif M, Fillet M, et al. Discovery and biochemical characterisation
of four novel biomarkers for osteoarthritis. Ann Rheum Dies 2011;70:
1144–52.
77 Onnerfjord P, Khabut A, Reinholt FP, et al. Quantitative proteomic analysis of eight
cartilaginous tissues reveals characteristic differences as well as similarities between
subgroups. J Biol Chem 2012;287:18913–24.
78 Castro-Perez JM, Kamphorst J, Degroot J, et al. Comprehensive LC-MS E lipidomic
analysis using a shotgun approach and its application to biomarker detection and
identiﬁcation in osteoarthritis patients. J Proteome Res 2010;9:2377–89.
79 Gobezie R, Kho A, Krastins B, et al. High abundance synovial ﬂuid proteome:
distinct proﬁles in health and osteoarthritis. Arthritis Res Ther 2007;9:R36.
80 Ritter SY, Subbaiah R, Bebek G, et al. Proteomic analysis of synovial ﬂuid from the
osteoarthritic knee: comparison with transcriptome analyses of joint tissues. Arthritis
Rheum 2013;65:981–92.
81 Hunter DJ, Nevitt M, Losina E, et al. Biomarkers for osteoarthritis: current position
and steps towards further validation. Rheum Dies Clin North Am 2013 In press.
82 Charni-Ben TN, Desmarais S, Bay-Jensen AC, et al. The type II collagen fragments
Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen
degradation. Osteoarthritis Cartilage 2008;16:1183–91.
83 Manno RL, Bingham CO III, Paternotte S, et al. OARSI-OMERACT initiative:
deﬁning thresholds for symptomatic severity and structural changes in disease
modifying osteoarthritis drug (DMOAD) clinical trials. Osteoarthritis Cartilage
2012;20:93–101.
84 van Spil WE, Jansen NW, Bijlsma JW, et al. Clusters within a wide spectrum of
biochemical markers for osteoarthritis: data from CHECK, a large cohort of
individuals with very early symptomatic osteoarthritis. Osteoarthritis Cartilage
2012;20:745–54.
85 Bos SD, Beekman M, Maier AB, et al. Metabolic health in families enriched for
longevity is associated with low prevalence of hand osteoarthritis and inﬂuences OA
biomarker proﬁles. Ann Rheum Dis 2013;72:1669–74.
Lotz M, et al. Ann Rheum Dis 2013;72:1756–1763. doi:10.1136/annrheumdis-2013-203726 1763
Review
group.bmj.com on July 26, 2017 - Published by http://ard.bmj.com/Downloaded from 
status and perspectives
Value of biomarkers in osteoarthritis: current
Reiter-Niesert, R Rizzoli, L J Sandell, W E Van Spil and J-Y Reginster
Kraus, W F Lems, I Meulenbelt, J-P Pelletier, J-P Raynauld, S
Chapurlat, J Collette, C Cooper, G Giacovelli, J A Kanis, M A Karsdal, V 
M Lotz, J Martel-Pelletier, C Christiansen, M-L Brandi, O Bruyère, R
doi: 10.1136/annrheumdis-2013-203726
2013
2013 72: 1756-1763 originally published online July 29,Ann Rheum Dis 
 http://ard.bmj.com/content/72/11/1756
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://ard.bmj.com/content/72/11/1756
This article cites 80 articles, 15 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/3.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 3.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Errata
 /content/early/2017/05/25/annrheumdis-2013-203726corr1.full.pdf
 or: page
nextAn erratum has been published regarding this article. Please see 
Collections
Topic Articles on similar topics can be found in the following collections 
 (611)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on July 26, 2017 - Published by http://ard.bmj.com/Downloaded from 
Correction
Based on information provided by the World Health Organization (WHO), the authors wish
to correct statements implying any formal collaboration agreements between WHO and the
University of Shefﬁeld, including its Metabolic Bone Disease Unit or Dr. John Kanis, after
January 2010.
10.1136/annrheumdis-2013-203726
Ann Rheum Dis 2017;0:1. doi:10.1136/annrheumdis-2013-203726corr1
Ann Rheum Dis Month 2017 Vol 0 No 0 1
Miscellaneous
 ARD Online First, published on May 25, 2017 as 10.1136/annrheumdis-2013-203726corr1
Copyright Article author (or their employer) 2017. Produced by BMJ Publishing Group Ltd (& EULAR) under licence. 
